The rising prevalence in GLP-1 agonists for metabolic conditions has led to a debate about delivery methods : patches versus tablets . Typically, GLP-1 therapies were exclusively available in oral https://kobipesf313283.bloginder.com/41586421/glp-1-skin-applications-vs-oral-medications-what-right-for-the-patient